Meanwhile, Sena et al.’s study [19] aimed to enhance the efficacy of anti-PD1 therapy by consolidating a multicentre cohort of 65 mismatch repair-deficient (dMMR) prostate cancer patients, 19 of whom received anti-PD1 treatment. The gene discussed is PDCD1; the disease is prostate carcinoma.